Journal
CLINICAL ENDOCRINOLOGY
Volume 86, Issue 3, Pages 419-424Publisher
WILEY
DOI: 10.1111/cen.13180
Keywords
-
Categories
Funding
- Genzyme
Ask authors/readers for more resources
ObjectiveThyroglobulin (Tg) is an excellent tumour marker, as detectable or increasing Tg levels are highly indicative of persistent or recurrent differentiated thyroid carcinoma (DTC). The clinical value of a highly sensitive (hs)-Tg assay in patients with DTC has not yet been established. The aim of this study was to investigate the additional value of unstimulated hs-Tg measurements (Tg-on) compared to stimulated IRMA-Tg measurements (Tg-off) in the follow-up of patients with DTC. Design, patients, measurementsWe retrospectively studied patients treated for DTC between 2006 and 2013 and compared hs-Tg and IRMA-Tg measurements. The study group consisted of 99 DTC patients in remission; Tg-on was measured 3 months after remnant ablation and Tg-off 6 months after ablation. ResultsIn the study group, 44 patients showed a hs-Tg-on <015 g/l (functional sensitivity); of these, 43 had an IRMA-Tg-off measurement <10 g/l, resulting in a negative predictive value of 977% and a positive predictive value of 564%. ConclusionsThe hs-Tg-on measurement is able to predict patients with an IRMA-Tg-off <10 g/l, and therefore decreases the need for Tg stimulation after ablation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available